Prevention of cancer is one of the key objectives of IARC. Secondary prevention by early diagnosis and screening is a fundamental component of any cancer control programme. The aim of secondary prevention is to reduce mortality and suffering from the disease. When screening is planned as part of a cancer control programme, only strategies proved to be effective should be proposed to the general population. Screening usually requires repeated interactions between ‘healthy’ individuals and health care providers, which can be inconvenient and costly. Furthermore, screening requires an ongoing commitment between the public and health care providers.

Scope
Cochrane (1972) first discussed the concepts of efficacy and effectiveness in the context of health interventions. Efficacy was later defined by Last (1995) as "the extent to which a specific intervention, procedure or service produces a beneficial result under ideal circumstances". In contrast, the related term "effectiveness" is defined by the same author as "... a measure of the extent to which a specific intervention, procedure, regimen or service, when deployed in the field in routine circumstances, does what it is intended to do for a specific population." The distinction between efficacy as measured in experimental studies and the effectiveness of a mass population intervention is a crucial one for public health decision-making. In particular, the fact that the effectiveness of a screening procedure may be different in different populations is often overlooked. A mass programme of screening must satisfy certain minimal requirements (e.g. acceptability, availability of relevant personnel, facilities for screening and access to pertinent health services) if it is to achieve the results that have been documented in epidemiological studies. The acceptance and use of screening services may vary from one population to another, implying that a given screening procedure is not universally effective. However, uncontrolled interventions in which individuals are exposed to unknown risks and benefits should be avoided.

Objectives
The objectives of the Working Group are:
(1) to evaluate the strength of the evidence for the efficacy of a screening procedure;
(2) to assess the effectiveness of defined screening interventions in defined populations;
(3) to assess the balance of benefit and harm in target populations; and
(4) to formulate recommendations for further research and for public health action.

The conclusions of the Working Group are published as a volume in the series of the IARC Handbooks of Cancer Prevention.

Working groups
An international working group of experts is convened by the IARC. The tasks of the group are:
(1) to ascertain that all appropriate data have been retrieved;
(2) to select the data relevant for evaluation on the basis of scientific merit;
(3) to prepare accurate reviews of data to allow the reader to follow the reasoning of the working group;
(4) to evaluate the efficacy and effectiveness of the screening procedure;
(5) to summarize the potential adverse consequences of screening;
(6) to prepare recommendations for research and for public health action; and
(7) to prepare an overall evaluation of the screening procedure at the population level.

Approximately 13 months before a working group meets, the topics of the Handbook are announced, and prospective participants are selected by IARC staff in consultation with other experts. Working group participants who contributed to the considerations and evaluations within a particular handbook are listed, with their
addresses, at the beginning of each publication. Each participant serves as an independent scientist and not as a representative of any organization, government or industry. They are expected to put aside any stake they may have in a particular outcome and to evaluate the evidence objectively and with scientific rigour. All participants are required to complete a form before the meeting on which they declare any potential conflict of interest, due for example to recent links with commercial or industrial bodies that have a stake in the outcome of the meeting. Participants who declare any such potential conflict of interest are excluded from chairing the meeting or any of its subgroups, from drafting evaluations and from any voting that may be involved in reaching the final conclusions. They may otherwise participate fully in the meeting, and are designated in the list of participants (pages vii-viii) as ‘invited experts’.

Scientists nominated by national and international agencies, industrial associations and consumer and/or environmental organizations may be invited as observers. IARC staff members involved in the preparation of the handbook are listed as secretariat.

Subsequently, relevant data are collected by the IARC from all available sources of published information. About eight months before the meeting, the material collected is sent to meeting participants who are asked to prepare sections for the first drafts of the handbook. These drafts are then compiled by IARC staff and sent, before the meeting, to all participants of the working group for review.

**Data for handbooks**
The handbooks do not necessarily cite all of the literature on the agent or strategy being evaluated. Only those data considered by the working group to be relevant to making the evaluation are included. Meeting abstracts and other reports that do not provide sufficient detail upon which to base an assessment of their quality are generally not considered.

With regard to reports of basic scientific research, epidemiological studies and clinical trials, only those that have been published or accepted for publication in the openly available scientific literature are reviewed by the working group. In certain instances, government agency reports that have undergone peer review and are widely available are considered. Exceptions may be made *ad hoc* to include unpublished reports that are in their final form and publicly available, if their inclusion is considered pertinent to making a final evaluation.

The available studies are summarized by the working group. In general, numerical findings are indicated as they appear in the original report; units are converted when necessary for easier comparison. The working group may conduct additional analyses of the published data and use them in their assessment of the evidence. These analyses are described in the handbook. Important aspects of a study, directly impinging on its interpretation, are brought to the attention of the reader.

**Evaluation of screening**
The framework of a handbook on screening includes the following eight chapters:

**Chapter 1. Disease characteristics, global burden and rationale for screening**

**Descriptive epidemiology**
The purpose of this section is to document the importance of the disease in the context of the general health status of different populations. The worldwide burden of the cancer is described (mortality, incidence, prevalence and survival rates) and integrated with measures of the occurrence of cancers at other sites, of mortality from all causes and life expectancy. Expected trends in the absence of screening are a relevant component of this section.

**Natural history of the disease as relevant to screening**
In this section, the natural history of the disease of interest and the relevance and potential of screening for early detection and for reducing mortality are described. Evolving concepts and principles pertinent to screening are also discussed.

There is now a wealth of evidence (both direct and indirect) to support the principle that screening and detection of certain cancers in appropriate target populations are associated with a lower probability of dying from the disease. The scheme (on the next page) illustrates the temporal framework commonly subscribed to in modern screening models.

It should be noted that early diagnosis, due to greater awareness and improved access to appropriate medical services, has resulted in many countries in a reduction in diagnostic delay, probably reducing mortality. As a consequence, symptomatic cancers are frequently diagnosed and treated early after the onset of symptoms in many developed nations. In such instances, screening for the disease will improve outcomes (for example, reducing mortality) only if treatment of the disease at an even earlier phase in its development provides additional benefit. The rapid evolution of molecular or genetic markers of pre-malignant conditions or individuals at high risk has modified the concepts of ‘disease onset’ and ‘lead time’. Hence, the model outlined above may require adaptation or development to allow for detection of pre-clinical conditions of undetermined significance (including serological and molecular markers and genetic predisposition), if they are relevant for screening for the cancer in question.

**Chapter 2. Screening tests**
It is important to distinguish between
screening tests and screening procedures, i.e. the test itself and the way in which it is administered. The two merit separate, detailed evaluation. Each of the screening tests to be considered is described. The ability of each test to detect cancer and to distinguish cancer from non-cancer conditions will be assessed as:

- the validity of the test, expressed as its sensitivity and specificity under various conditions;
- all known or potential side-effects; and
- the cost of the test when implemented in mass screening programmes.

Chapter 3. Delivery and uptake of screening

Information on how screening is delivered in different countries is reviewed in this section, with emphasis on the following aspects:

- infrastructure for diagnosis and treatment: the nature of standard diagnostic procedures and treatment regimens and their availability to the target population;
- extent of population coverage and participation rates;
- equity, as defined by the extent to which access to the procedure (including diagnostic investigation and treatment) is ensured for all eligible individuals, irrespective of any personal characteristics;
- informed decision and informed consent: the extent to which individual values are respected when information on potential benefit and harm is conveyed; and

- behavioural and demographic considerations that affect participation in screening.

Chapter 4. Efficacy of screening tests

In this section, evidence from epidemiological studies is reviewed, and aspects of study design and analysis are critically discussed. The handbooks are not intended to summarize all published studies. The working group considers the following aspects:

1. the relevance of the study;
2. the appropriateness of the design and analysis to the question being asked;
3. the adequacy and completeness of the presentation of the data; and
4. the degree to which chance, bias and confounding may have affected the results.

Studies that are judged to be inadequate or irrelevant to the evaluation are generally omitted. They may be mentioned briefly (i) when the information is considered to be a useful supplement to that in other reports, (ii) if they provide the only data available or (iii) in exceptional cases, if they have been widely perceived as being pertinent but are deemed otherwise by the working group. Their inclusion does not imply acceptance of the adequacy of the study design nor of the analysis and interpretation of the results, and their limitations are outlined.

In evaluating case–control and cohort studies, particular attention is paid to the definition of cases, controls and exposure and, for cohort studies, the length and completeness of follow-up. Potential bias, especially selection bias, is carefully examined in all observational studies.

Chapter 5. Effectiveness of population-based screening

The impact of the screening procedure when implemented in defined populations is examined in this section. Indicators used to monitor effectiveness, such as positive and negative predictive values, detection rate, rates of interval cancers and the number of tests performed, are reported. Time trends before and after implementation of screening as well as geographical comparisons of the occurrence of the disease and death from the disease in populations exposed and not exposed to screening are reviewed and interpreted. In doing this, the Working Group takes into account differences in important in evaluating experimental studies are: the selection of participants, the nature and adequacy of the randomization procedure, evidence that randomization achieved an adequate balance between the groups, the exclusion criteria used before and after randomization, compliance with the intervention in the screened group and ‘contamination’ with the intervention in the control group. Other considerations are the means by which the end-point was determined and validated (either by screening or by other means of detection of the disease), the length and completeness of follow-up of the groups and the adequacy of the analysis. Whenever possible, similar criteria should be used to evaluate non-experimental comparative studies.

In the Working Group’s analysis of the efficacy of the screening procedure, a meta-analysis may be used, when applicable.

In evaluating case–control and cohort studies, particular attention is paid to the definition of cases, controls and exposure and, for cohort studies, the length and completeness of follow-up. Potential bias, especially selection bias, is carefully examined in all observational studies.

References
screening procedures (e.g. frequency and the age of the target population) and of participation rates.

An integral component of this section is an evaluation of the benefits and harms of the screening procedure to the population. Reductions in mortality and/or incidence of invasive disease are fundamental measures of benefit. An additional benefit is that more cases can be treated by less aggressive, less invasive procedures, thus improving the quality of life.

The spectrum of health care is dynamic, and a screening procedure should not be viewed in isolation. Greater awareness of the disease, brought about by publicity about screening that may result in early diagnosis, could be regarded as another benefit of a screening programme. This section should also consider the possibility that there might have been a change in treatment of the cancer, which even in the absence of screening would have resulted in a substantial decrease in mortality. As far as possible, an evaluation should be made of the extent to which improved treatment has been responsible for any changes seen in mortality from the specific disease.

Estimates of the rates of false-positive and false-negative findings in screened individuals and their consequences (false sense of security with false-negatives and false alarm with false-positives) are an integral part of this section. The rates of short- and long-term side-effects and the possibility of unnecessary treatment of borderline or indolent cases detected at screening are discussed. Management procedures for lesions detected at screening are reviewed. Psychological factors, such as anxiety induced by undergoing the test procedure, are also considered.

Finally, the cost-effectiveness of various modalities of test administration in various settings is considered. The discussion takes into account the costs per case detected and per death prevented.

Chapter 6. Summary of data
In this section, the relevant data are summarized. Inadequate studies identified in the preceding text are generally not included.

Chapter 7. Evaluation
Evaluation of the efficacy of the screening procedure
An evaluation of the degree of evidence for the efficacy of a screening procedure is formulated according to the following definitions:

- **Sufficient evidence of the efficacy of cancer-preventive activity** will apply when screening interventions by a defined procedure are consistently associated with a reduction in mortality from the cancer and/or a reduction in the incidence of invasive cancer, and chance and bias can be ruled out with reasonable confidence.

- **Limited evidence of the efficacy of cancer-preventive activity** will apply when screening interventions by a defined procedure are associated with a reduction in mortality from the cancer and/or a reduction in the incidence of invasive cancer or a reduction in the incidence of clinically advanced cancer, but bias or confounding cannot be ruled out with reasonable confidence as alternative explanations for these associations.

- **Inadequate evidence of the efficacy of cancer-preventive activity** will apply when data are lacking or when the available information is insufficient or too heterogeneous to allow an evaluation.

In the case of limited or inadequate evidence, the Working Group should highlight those aspects of the procedure for which information is lacking and which led to the uncertainty in evaluation. This will provide indications of research priorities.

**Overall evaluation**
Finally, the body of evidence is considered as a whole, and summary statements are made about the cancer-preventive effects of the screening intervention in humans and other beneficial or adverse effects, as appropriate. The overall evaluation is usually in the form of a narrative. The data on the effectiveness of the screening intervention are summarized, including the factors that determine its success and failure under routine conditions. Finally, the balance between expected benefit and harm is described.

Chapter 8. Recommendations
After its review of the data and its deliberations, the working group formulates recommendations, where applicable, for:

- further research and
- public health action.

**References**